Probatebeta
Target

GABRB3

Gamma-aminobutyric acid receptor subunit beta-3

As of the edition of 20 October 2026, GABRB3 (gamma-aminobutyric acid receptor subunit beta-3, UniProt P28472) has 13 drugs tested at it and 11 companies on the list, 1 on route A and 2 on route B.

Sources: UniProt, ClinicalTrials.gov, ChEMBL, FDA Orange Book and Purple Book, Pharos.

The protein

UniProt
P28472
How well studied
Drug target: an approved drug acts on it
Where it sits in the cell
At a membrane
Solved structures
109
Disease areas
Nervous system; Mental health; Heart and blood vessels; Eye; Injuries; Nutrition and metabolism
Registered trials of its drugs
23

Drugs at this target

StatusCount
Marketed11
Went quiet1
Withdrawn from market1
Total13
DrugStatusFurthest phaseUS protection
ThiopentalMarketedPhase 4none listed
PrimidoneMarketedPhase 2none listed
PentobarbitalWithdrawn from marketPhase 3none listed
MethohexitalMarketedPhase 4none listed
ClomethiazoleMarketedPhase 3none listed
EtazolateWent quietPhase 2none listed
ButabarbitalMarketedNo phase statednone listed
ButalbitalMarketedNo phase statednone listed
MeprobamateMarketedNo phase statednone listed
MetharbitalMarketedNo phase statednone listed
SecobarbitalMarketedNo phase statednone listed
TalbutalMarketedNo phase statednone listed

12 of 13 drugs, the most tested first.

Companies at this target

Where the company standsCompanies
Route A1
Route B2
Undetermined8
Total on the list11
Three companies on route A or B, with the route only
CompanyRoute
PfizerRoute B
Apsen FarmaceuticaRoute B
ExonhitRoute A

The other 8 companies at GABRB3

In the product

11 companies in all; 8 are not named here, and no score is.

See the 11 companies at GABRB3, ranked, with the facts behind eachRequest access. Nothing is shown until you do.

Other targets in nervous system

Companies holding approvals at GABRB3